BINHUI BIOPHARM

Binhui Biopharmaceutical’s oncolytic virus candidate drug BS001 (OH2) received FDA approval for the clinical trial in multiple solid tumors

Author:bhsw  Date:2021-08-22 08:26:55  Views:

After starting the clinical trial in recurrent glioblastoma multiforme in Beijing Tiantan Hospital, Binhui Biopharmaceutical’s oncolytic virus candidate drug BS001 (OH2) received FDA approval for the clinical trial in multiple solid tumors in the US on August 20, 2021(EST).